Erratum : Are rates of vision loss in patients in English glaucoma clinics slowing down over time Trends from a decade of data (Eye (2015) 29, 1613-1619; DOI:10.1038/eye.2015.161);Are rates of vision loss in patients in English glaucoma clinics slowing down over time Trends from a decade of data

Eye (Basingstoke)

Volumn 29, Issue 12, 2015, Pages 1613-1619

  Boodhna, T ^a   Saunders, L J ^a   Crabb, D P ^a  

^a CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; GLAUCOMA; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; UNITED KINGDOM; VISUAL FIELD; VISUAL IMPAIRMENT; FEMALE; GREAT BRITAIN; MALE; MIDDLE AGED; OPTIC NERVE DISEASES; PERIMETRY; VISION DISORDERS;

AGED; FEMALE; GLAUCOMA; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; OPTIC NERVE DISEASES; RETROSPECTIVE STUDIES; VISION DISORDERS; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84949545684     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.186     Document Type: Erratum

References (38)

1. Heijl A, Buchholz P, Norrgren G, Bengtsson B. Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol 2012; 91(5): 406-412.
2. Chauhan BC. Group CGS Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. Can J Ophthalmol 2006; 41(5): 566-575.
3. De Moraes CGV, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R et al. Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol 2011; 129(5): 562-568.
4. Chauhan BC, Malik R, Shuba LM, Rafuse PE, Nicolela MT, Artes PH. Rates of glaucomatous visual field change in a large clinical population. Invest Ophthalmol Vis Sci 2014; 55(7): 4135-4143.
5. Keenan T, Johnston R, Donachie P, Sparrow J, Stratton I, Scanlon P. United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye 2013; 27(12): 1397-1404.
6. Tufail A, Xing W, Johnston R, Akerele T, McKibbin M, Downey L et al. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections. Ophthalmology 2014; 121(5): 1092-1101.
7. Sparrow J, Taylor H, Qureshi K, Smith R, Birnie K, Johnston R. The Cataract National Dataset electronic multi-centre audit of 55 567 operations: risk indicators for monocular visual acuity outcomes. Eye 2012; 26(6): 821-826.
8. Butt T, Lee A, Lee C, Tufail A, Xing W, Johnston RL et al. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes. BMJ Open 2015; 5(5): e006535.
9. Boodhna T, Crabb DP. Disease severity in newly diagnosed glaucoma patients with visual field loss: trends from more than a decade of data. Ophthalmic Physiol Opt 2014; 35(2): 225-230.
10. Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. Invest Ophthalmol Vis Sci 2014; 55(1): 102-109.
11. Bateman D, Clark R, Azuara-Blanco A, Bain M, Forrest J. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol 2002; 86(5): 551-554.
12. Saunders LJ, Russell RA, Crabb DP. Practical landmarks for visual field disability in glaucoma. Br J Ophthalmol 2012; 96: 1185-1189.
13. Wild JM, Dengler-Harles M, Searle AET, O'Neill EC, Crews SJ. The influence of the learning effect on automated perimetry in patients with suspected glaucoma. Acta Ophthalmol (Copenh) 1989; 67: 537-545.
14. Heijl A, Lindgren G, Olsson J. The effect of perimetric experience in normal subjects. Arch Ophthalmol 1989; 107(1): 81-86.
15. Heijl A, Bengtsson B. The effect of perimetric experience in patients with glaucoma. Arch Ophthalmol 1996; 114(1): 19-22.
16. Jansonius N. On the accuracy of measuring rates of visual field change in glaucoma. Br J Ophthalmol 2010; 94(10): 1404-1405.
17. Hodapp E, Parrish RI, Anderson DR. Clinical Decisions in Glaucoma. The CV Mosby: St Louis, MO, 1993.
18. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2008.
19. Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 2014; 385(9975): 1295-1304.
20. Owen CG, Carey I, De Wilde S, Whincup P, Wormald R, Cook D. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol 2006; 90(7): 861-868.
21. Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51(9): 1574-1580.
22. Holekamp NM, Liu Y, Yeh W-S, Chia Y, Kiss S, Almony A et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol 2014; 157(4): 825-833 e1.
23. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008; 126(8): 1030-1036.
24. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114(11): 1965-1972.
25. Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004; 111(9): 1627-1635.
26. Drance S, Anderson DR, Schulzer M. Group CN-TGS Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001; 131(6) 699-708.
27. Prata TS, De Moraes CG, Teng CC, Tello C, Ritch R, Liebmann JM. Factors affecting rates of visual field progression in glaucoma patients with optic disc hemorrhage. Ophthalmology 2010; 117(1): 24-29.
28. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121(1): 48-56.
29. Wesselink C, Stoutenbeek R, Jansonius N. Incorporating life expectancy in glaucoma care. Eye 2011; 25(12): 1575-1580.
30. Russell RA, Crabb DP, Malik R, Garway-Heath DF. The relationship between variability and sensitivity in large-scale longitudinal visual field data. Invest Ophthalmol Vis Sci 2012; 53(10): 5985-5990.
31. Fung SS, Lemer C, Russell RA, Malik R, Crabb DP. Are practical recommendations practiced? A national multi-centre cross-sectional study on frequency of visual field testing in glaucoma. Br J Ophthalmol 2013; 97(7): 843-847.
32. Crabb D, Russell R, Malik R, Anand N, Baker H, Boodhna T et al. Frequency of visual field testing when monitoring patients newly diagnosed with glaucoma: mixed methods and modelling. Health Serv Deliv Res 2014; 2(27): 49-77.
33. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd edn. Editrice Dogma: Savona, Italy, 2008.
34. Malik R, Baker H, Russell RA, Crabb DP. A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines. BMJ Open 2013; 3(5): e002067.
35. Glen FC, Baker H, Crabb DP. A qualitative investigation into patients' views on visual field testing for glaucoma monitoring. BMJ Open 2014; 4(1): e003996.
36. Chauhan BC, Garway-Heath DF, Goni FJ, Rossetti L, Bengtsson B, Viswanathan AC et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2008; 92(4): 569-573.
37. Crabb DP, Garway-Heath DF. Intervals between visual field tests when monitoring the glaucomatous patient: wait-and-see approach. Invest Ophthalmol Vis Sci 2012; 53(6): 2770-2776.
38. Jansonius NM. Progression detection in glaucoma can be made more efficient by using a variable interval between successive visual field tests. Graefes Arch Clin Exp Ophthalmol 2007; 245(11): 1647-1651.